Condition: Thymoma · Thymic Carcinoma · Sponsor: Georgetown University
The goal of this clinical trial is to study the effect of sacituzumab govitecan-hziy in adult patients with advanced thymoma and thymic carcinoma after progressing on at least one prior line of therapy. The main question it aims to answer is: • What is the overall response rate (ORR) in patients with advanced thymoma and thymic carcinoma? Participants will: * receive a fixed dose of 10 mg/kg given intravenously, once weekly on Days 1 and 8 of continuous 21-day treatment cycles until disease progression or unacceptable toxicity * have regular blood tests, scans, and examinations to monitor their health. * have blood and a biopsy of their tumor for research purposes.
This description comes directly from the study's public registry record.
Chul Kim, MD · 202-444-2223 · Chul.Kim@gunet.georgetown.edu
Always discuss trial participation with your own doctor first.
| Stanford Cancer Institute | Palo Alto, California, United States | Recruiting |
| Lombardi Comprehensive Cancer Center, Georgetown University | Washington D.C., District of Columbia, United States | Recruiting |
| University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06248515